Comparing hormone markers in first and returning breast cancer
Part of Cancer, Skin clinical trials.
This trial looks at how certain proteins (ER, PR, and HER2/neu) on breast cancer cells change when the cancer comes back in the same spot. Knowing this could help doctors choose the best treatment for your recurrence.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had surgery to remove a breast cancer tumor.
- That same breast cancer came back in the same area.
- Your doctors checked ER, PR, and HER2/neu levels on both the first tumor and the one that returned.
- You have enough medical records to see those test results.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial checks whether specific “surveillance” markers (measured from blood and bone marrow) can help predict if breast cancer comes back after standard treatments. It may help doctors monitor you more accurately and earlier if recurrence risk is high.
This trial looks at factors that may predict whether hormone receptor–positive breast cancer will come back after you’ve already completed 5 years of hormone (endocrine) therapy. It may help identify who benefits most from longer treatment and follow-up.
This trial uses a blood test to look for tiny bits of tumor DNA after treatment. If found, participants receive new drug combinations to try to prevent cancer from returning.
This study follows people who have had breast cancer come back in the same area after surgery. It looks at how well re-treatment works and helps doctors understand how to manage this type of recurrence.
This study tracks tiny traces of cancer DNA in the blood over time to see if it can find early signs of breast cancer coming back. It looks at different types of breast cancer and at different points in a patient's treatment journey.
This study looks at proteins and imaging patterns (from tissue, fluid near the tumor, and blood) to better understand breast cancer markers. It may help researchers find clues that doctors can use to evaluate breast nodules and newly diagnosed invasive breast cancer.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.